Related Experiment Video
Updated: Jul 2, 2025
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Low-Dose Apalutamide in Nonmetastatic Castration-Resistant Prostate Cancer: A Case Report
Minh Dung Nguyen1, Gilles Natchagande2, Olena Gorobets3
1Orthopedics and Sport Medicine, Hospital of Orthopedics and Rehabilitation, Ho Chi Minh City, VNM.
Abstract:
The effect of low-dose apalutamide in nonmetastatic castration-resistant prostate cancer is unknown. We report the observation of therapy being administered at 25% of the recommended dose in an 80-year-old patient. Despite treatment discontinuation during COVID lockdowns, he survived three years without evidence of metastasis. This case gently invites us to reflect on the possibility of low-dose apalutamide in the elderly.
